TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of Urinary Calcium Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Gy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Patient's Assessment of Sleep Disturbances for the Last 24 Hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Physician's Assessment of Sleep Disturbances
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion of patients who are progression-free at one year
Endpoint domain: Mortality/survival
Primary endpoint: Regular Menstruation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Electromagnetic interference of the ICD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD)/recommended phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Health Questionnaire-8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of total study population with Adverse Events graded as Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Significant Improvement in Myoelectric Control Using the Assessment of Capacity for Myoelectric Control (ACMC) Functionality Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal sensitivity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of physicians with accurate knowledge of safety information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients with accurate knowledge of safety information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of recurrent isthmus conduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in symptoms of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive viral DNA or RNA result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Positive viral antibody result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pro-Inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxidative Stress markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Punctate Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rate of anosmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shorten recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal change in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Achievement of complete remission/complete remission with incomplete marrow recovery and bone marrow minimal residual disease-negative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Serum Pro-collagen 1 Intact N-terminal Propeptide (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Exhibiting Natural Killer Cell Expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Height SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ONH pressure-flow relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occlusion and restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Variation trend of electric conductivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type 2 diabetes mellitus incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chronic liver diseases incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyslipidemia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Emergent Antibody Response (TEAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Volume of blood loss at the time of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Spatial learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of E7777
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of cardiac arrythmic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Upregulation of anabolic signaling molecules and genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Downregulation of catabolic signaling molecules and genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Children's Depression Rating Scale - Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Condomless Anal Sex
Endpoint domain: Adverse events/effects
Primary endpoint: subject recruitment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: subject drop out rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of missing values
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of submitted incorrect values
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: C-terminal telopeptide of type I collagen (CTx-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total procollagen type 1 amino-terminal propeptide (P1NP) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response to treatment measured by change in Sensory Organization Test (SOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated intensity of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of the vaginal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tasks completion success
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Numbers of tasks errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System usability scale (SUS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Risk Perception changes amongst young adults
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of Admission at the Ward in Days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in Edmonton Symptom Assessment Score (ESAS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Performance (Baseline)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Performance (Post-test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Performance (Retention)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prolonged abstinence from waterpipe smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak serum cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Presence of gastric and/or duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Congruence with the evidence-based nutrition practice guideline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOL power selection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of a clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in radiographic bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing Device Related Events
Endpoint domain: Adverse events/effects
Primary endpoint: sexual risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: time to return of normal bladder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: plasma levels of alpha linolenic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hormone profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: System Usability Scale (SUS) for iCO monitor and Stay Quit Coach (SQC) App
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total number of treatment sessions completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CIPNM on day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing Anaphylactic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Experiencing Hypersensitivity Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Experiencing Potential Infusion-Related Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in video Ocular Protection Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Mild, Moderate and Severe TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Endometrial Hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Endometrial Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: prevalence rate of unspecified eating disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of treatment-related, dose-limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Nailfold capillary number of tortuous loops
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nailfold capillary area number of meandering capillaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nailfold capillary avascular areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Independence with Adequate Control of Blood Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Red blood cell velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in Hair Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Hospitalized for Cardiovascular Reasons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pHRM from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sydney Swallowing Questionnaire between timepoints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Hand Grip Strength Test between timepoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Target Area Hair Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in shape of anorectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Freedom from device- or femoral artery access-related major adverse events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Kansas City Cardiomyopathy Questionnaire Quality of Life Questionnaire (KCCQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 6-Minute Walk Test (6MWT) distance (m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Patient-Reported Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fraction of healthcare workers infected with SARS-CoV-2
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability Test - Related Withdrawals
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of adverse events and serious adverse events related to GW003
Endpoint domain: Adverse events/effects
Primary endpoint: On time without troublesome dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Increases in child support payment modifications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increases in monthly child support payment amounts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increases in employment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Increases in receipt of public assistance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cumulative Dose of Sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of participants who have access to care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Physical Activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Dietary Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Number of blood donations of CD34+ stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of Ventilator-Associated Pneumonia (VAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Modified Sensory Organization Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper extremity function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of HCC
Endpoint domain: Mortality/survival
Primary endpoint: Mean change from baseline FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in average number of micturitions per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in average number of urge incontinence episodes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hours of use per patient per month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fatigue change measured by VAS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Participants With Clinically Significant Physical Examination Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Markedly Abnormal Values of Vital Signs Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weaning time of catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of microscopic hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urinary outcomes
Primary endpoint: Time course of the pharmacodynamic effect of atracurium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of cefazolin in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of morphine and metabolites in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time course of anti-factor Xa levels in blood following nadroparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parental report of psychological difficulties
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Diffusivity (MD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maturation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary assisted patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Calculated Knee Society Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and types of recurrent genomic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for mental fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Mass Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy for Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-regulation of Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in walking distance during the 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Score Using Wong Baker/FACES (age<11yr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Score Using Numeric Rating Scale (age>11yr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fractional oxygen extraction (FOE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotidal Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Global Spontaneous Pain Intensity of Target Hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Index for Hand Osteoarthritis Dreiser's Score (FIHOA) in the Target Hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of pulmonary alveolar proteinosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prognosis of pulmonary alveolar proteinosis
Endpoint domain: Mortality/survival
Primary endpoint: postoperative infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Figure-of-Eight Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve last (AUClast) of Erythropoietin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum of concentration (Cmax) of Erythropoietin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reticulocyte count (%) compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in MDP using the 14-point MEDAS scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in PA using activity monitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate: a ≥ 50% reduction in number of urgency related incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: device- and procedure-related Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: MOR binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full skin thinning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Measurement of melanin index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Measurement of erythema index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Measurement of post-acne hyperpigmentation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of immobilisation induced bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Heavy Episodic (Binge) Drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CELF-4 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CELF-P Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes